Sinonasal Undifferentiated Carcinoma

MONDO:0006411 Pathograph 6 Show in embeddings browser undifferentiated carcinoma

Sinonasal undifferentiated carcinoma (SNUC) is a rare, high-grade epithelial malignancy of the nasal cavity and paranasal sinuses, defined by an undifferentiated morphology with no squamous or glandular differentiation and no evidence of Epstein-Barr virus association. It was long a diagnosis of exclusion, but molecular profiling has established a dominant driver: a neomorphic IDH2 R172 hotspot mutation, reported in 55% to more than 80% of cases, which produces a global DNA and H3K27 hypermethylator phenotype and segregates SNUC (together with IDH2-mutant large cell neuroendocrine carcinoma) from its histologic mimics — olfactory neuroblastoma, SMARCB1-deficient sinonasal carcinoma, and small cell neuroendocrine carcinoma. IDH2-wild-type tumors instead carry SMARCA4, NOTCH1, or TET2 alterations. Cooperating TP53 mutation and CDKN2A/2B loss are frequent within IDH2-mutant tumors. Clinically SNUC presents late with bulky disease invading the orbit and anterior skull base, and outcome depends heavily on response to induction chemotherapy, which is used both as therapy and as a biological test to select between definitive chemoradiotherapy and surgery.

Ask OpenScientist

Ask a research question about Sinonasal Undifferentiated Carcinoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
3
Histopath.
5
Phenotypes
6
Pathograph
5
Genes
4
Medical Actions
2
Differentials
2
Trials
1
Deep Research
⚙

Pathophysiology

5
IDH2 R172 Neomorphic Hotspot Mutation
A somatic hotspot substitution at IDH2 residue R172 (R172S, R172T, R172M, and related variants) converts isocitrate dehydrogenase 2 into a neomorphic enzyme. This is the single most frequent recurrent alteration in SNUC, detected in 55% of cases in one targeted-sequencing series and in 82.4% in another, and it is essentially absent from the other head and neck tumor types tested. Mutant-specific IDH1/2 immunohistochemistry tracks the mutation, making it a practical diagnostic surrogate.
sinonasal epithelial cell CL:0000066 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves sinonasal epithelial cell, annotated with epithelial cell (CL:0000066). CL:0000066 is a cell type from the Cell Ontology.
isocitrate dehydrogenase (NADP+) activity GO:0004450 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves isocitrate dehydrogenase (NADP+) activity (GO:0004450), qualified as gain of function. GO:0004450 is a molecular function from the Gene Ontology. ⇑ GAIN OF FUNCTION
paranasal sinus UBERON:0001825 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in paranasal sinus (UBERON:0001825). UBERON:0001825 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
DNA and Histone Hypermethylator Phenotype Neomorphic IDH2 activity drives the global methylation phenotype that distinguishes IDH2-mutant sinonasal carcinomas.
Show evidence (2 references)
PMID:28084339 SUPPORT Human Clinical
"We identified IDH2 R172X mutations in 55% of sinonasal undifferentiated carcinomas including R172S, R172T, and R172M."
Establishes IDH2 R172 hotspot substitution as a recurrent somatic driver in SNUC and names the specific residue changes.
PMID:28493366 SUPPORT Human Clinical
"IDH2 R172 single nucleotide variants were overall detected in 14 (82.4%) SNUCs"
Independent cohort giving a higher hotspot frequency, supporting IDH2 R172 mutation as the dominant molecular event rather than an incidental finding.
DNA and Histone Hypermethylator Phenotype
Mutant IDH2 induces a global hypermethylator state: genome-wide DNA methylation profiling separates IDH2-mutant sinonasal tumors into a single cluster irrespective of histologic type, and the tumors show increased repressive H3K27 trimethylation relative to IDH2-wild-type tumors. This epigenetic reprogramming, rather than a proliferative signaling lesion, is the proximate consequence of the driver mutation.
sinonasal epithelial cell CL:0000066 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves sinonasal epithelial cell, annotated with epithelial cell (CL:0000066). CL:0000066 is a cell type from the Cell Ontology.
negative regulation of gene expression via chromosomal CpG island methylation GO:0044027 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased negative regulation of gene expression via chromosomal CpG island methylation (GO:0044027). GO:0044027 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Undifferentiated High-Grade Proliferation Widespread promoter and H3K27 hypermethylation is proposed to lock the sinonasal epithelium out of a differentiated program, leaving a high-grade undifferentiated tumor cell.
Show evidence (2 references)
PMID:31186531 SUPPORT Human Clinical
"IDH2 mutations in sinonasal carcinomas induce a hypermethylator phenotype and define a molecular subgroup of tumors arising in this location."
States directly that the IDH2 mutation induces the hypermethylator phenotype modeled by this node.
PMID:31186531 SUPPORT Human Clinical
"IDH2 mutants demonstrated a global methylation phenotype and an increase in repressive trimethylation of H3K27 in comparison to IDH2 wild-type tumors (p < 0.001)."
Quantifies both the DNA-methylation and the repressive histone-methylation arms of this node against an IDH2-wild-type comparator.
Cooperating Tumor Suppressor Loss
IDH2 mutation alone is not sufficient. Within IDH2-mutant SNUC, co-occurring TP53 mutation and CDKN2A/2B loss-of-function alterations are each present in roughly a third to two fifths of cases, disabling the p53 and RB antiproliferative axes. IDH2-wild-type tumors reach a comparable end by a different route, through SMARCA4 loss-of-function with confirmed loss of protein expression, NOTCH1 gain-of-function, or TET2 loss-of-function.
sinonasal epithelial cell CL:0000066 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves sinonasal epithelial cell, annotated with epithelial cell (CL:0000066). CL:0000066 is a cell type from the Cell Ontology.
signal transduction by p53 class mediator GO:0072331 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased signal transduction by p53 class mediator (GO:0072331). GO:0072331 is a biological process from the Gene Ontology. ↓ DECREASED chromatin remodeling GO:0006338 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased chromatin remodeling (GO:0006338). GO:0006338 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Undifferentiated High-Grade Proliferation Loss of the p53 and RB brakes, or of SWI/SNF chromatin-remodeling function, removes the antiproliferative control that would otherwise limit outgrowth of the transformed clone.
Show evidence (2 references)
PMID:28493366 SUPPORT Human Clinical
"Among 12 IDH2-mutated cases in cohort 1, five (41.7%) harboured co-existing TP53 mutations, four (33.3%) CDKN2A/2B loss-of-function alterations, four (33.3%) MYC amplification, and three (25%) had concurrent SETD2 mutations."
Quantifies co-occurring TP53 and CDKN2A/2B inactivation within IDH2-mutant SNUC, which is what this node claims and what grounds the conformance to the evading_growth_suppressors trigger.
PMID:28084339 SUPPORT Human Clinical
"Alterations in the IDH2-wild-type sinonasal undifferentiated carcinomas included SMARCA4 loss-of-function with confirmed loss of immunohistochemical expression, NOTCH1 gain-of-function, and TET2 loss-of-function."
Supports the alternative, IDH2-wild-type route to loss of growth suppression through SWI/SNF (SMARCA4) and TET2 inactivation.
Undifferentiated High-Grade Proliferation
The resulting tumor cell is undifferentiated and highly proliferative: cohesive nests, ribbons, and trabeculae of cells with hyperchromatic nuclei and a high nuclear-to-cytoplasmic ratio, a brisk mitotic rate, tumor necrosis, and vascular invasion. The absence of squamous or glandular differentiation is definitional and is what historically made SNUC a diagnosis of exclusion.
sinonasal epithelial cell CL:0000066 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves sinonasal epithelial cell, annotated with epithelial cell (CL:0000066). CL:0000066 is a cell type from the Cell Ontology.
cell population proliferation GO:0008283 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cell population proliferation (GO:0008283). GO:0008283 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Rapid Local Invasion of Orbit and Anterior Skull Base Rapid, poorly differentiated growth in an anatomically unconfined air-filled space produces early transgression of the sinus walls.
Show evidence (1 reference)
PMID:10562893 SUPPORT Human Clinical
"A brisk mitotic rate, tumor necrosis, and vascular invasion are prominent features."
Describes the high-grade proliferative and necrotic phenotype this node models.
Rapid Local Invasion of Orbit and Anterior Skull Base
Because the paranasal sinuses are air-filled spaces that produce few early symptoms, SNUC characteristically reaches the orbit, cribriform plate, and anterior cranial fossa before diagnosis. Advanced stage at presentation, high locoregional recurrence, and a tendency to metastasize together account for the poor prognosis.
paranasal sinus UBERON:0001825 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in paranasal sinus (UBERON:0001825). UBERON:0001825 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (1 reference)
PMID:30806835 SUPPORT Human Clinical
"SNUC usually presents at advanced stage and the prognosis is usually poor with high rates of locoregional recurrence and tendency to metastasize."
Supports advanced-stage local disease with high locoregional recurrence as the dominant clinical behavior of SNUC.
✶

Histopathology

3
Nuclear Pleomorphism
Cohesive cells with hyperchromatic nuclei and a high nuclear-to-cytoplasmic ratio arranged in nests, ribbons, and trabeculae.
Show evidence (1 reference)
PMID:10562893 SUPPORT Human Clinical
"The cells exhibit hyperchromatic nuclei and a high nuclear to cytoplasmic ratio."
Describes the nuclear morphology recorded by this finding.
Increased Mitotic Activity
A brisk mitotic rate is a prominent and expected feature of this high-grade carcinoma.
Show evidence (1 reference)
PMID:10562893 SUPPORT Human Clinical
"A brisk mitotic rate, tumor necrosis, and vascular invasion are prominent features."
Names brisk mitotic activity as a prominent histologic feature.
Tumor Cell Necrosis
Tumor necrosis accompanies the high proliferative rate and helps separate SNUC from lower-grade sinonasal mimics.
Show evidence (1 reference)
PMID:10562893 SUPPORT Human Clinical
"A brisk mitotic rate, tumor necrosis, and vascular invasion are prominent features."
Names tumor necrosis as a prominent histologic feature.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Sinonasal Undifferentiated Carcinoma Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

5
Blood 1
Epistaxis HP:0000421 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Epistaxis (HP:0000421). HP:0000421 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:10562893 SUPPORT Human Clinical
"Presenting symptoms include facial pain, nasal obstruction, diplopia, epistaxis, proptosis, and periorbital swelling."
Lists epistaxis among the presenting symptoms of SNUC.
Eye 2
Proptosis HP:0000520 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Proptosis (HP:0000520). HP:0000520 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:10562893 SUPPORT Human Clinical
"Presenting symptoms include facial pain, nasal obstruction, diplopia, epistaxis, proptosis, and periorbital swelling."
Lists proptosis among the presenting symptoms of SNUC.
Diplopia HP:0000651 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Diplopia (HP:0000651). HP:0000651 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:10562893 SUPPORT Human Clinical
"Presenting symptoms include facial pain, nasal obstruction, diplopia, epistaxis, proptosis, and periorbital swelling."
Lists diplopia among the presenting symptoms of SNUC.
Head and Neck 1
Nasal Obstruction Nasal congestion HP:0001742 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Nasal obstruction, annotated with Nasal congestion (HP:0001742). HP:0001742 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:10562893 SUPPORT Human Clinical
"Presenting symptoms include facial pain, nasal obstruction, diplopia, epistaxis, proptosis, and periorbital swelling."
Lists nasal obstruction among the presenting symptoms of SNUC.
Constitutional 1
Facial Pain HP:0012531 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Facial pain, annotated with Pain (HP:0012531). HP:0012531 is a phenotype from the Human Phenotype Ontology.
HP has no dedicated facial-pain class, so this is bound to the generic Pain term with a more specific preferred_term.
Show evidence (1 reference)
PMID:10562893 SUPPORT Human Clinical
"Presenting symptoms include facial pain, nasal obstruction, diplopia, epistaxis, proptosis, and periorbital swelling."
Lists facial pain among the presenting symptoms of SNUC.
🧬

Genetic Associations

5
IDH2 (Somatic hotspot mutation)
Gene: IDH2 hgnc:5383 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is IDH2 (hgnc:5383). hgnc:5383 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:28084339 SUPPORT Human Clinical
"We identified IDH2 R172X mutations in 55% of sinonasal undifferentiated carcinomas including R172S, R172T, and R172M."
Primary report of the recurrent IDH2 R172 hotspot in SNUC.
SMARCA4 (Somatic loss-of-function)
Gene: SMARCA4 hgnc:11100 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SMARCA4 (hgnc:11100). hgnc:11100 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:28084339 SUPPORT Human Clinical
"Alterations in the IDH2-wild-type sinonasal undifferentiated carcinomas included SMARCA4 loss-of-function with confirmed loss of immunohistochemical expression, NOTCH1 gain-of-function, and TET2 loss-of-function."
Supports SMARCA4 loss of function as a driver in the IDH2-wild-type subset, confirmed at the protein level.
TP53 (Co-occurring somatic mutation)
Gene: TP53 hgnc:11998 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TP53 (hgnc:11998). hgnc:11998 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:28493366 SUPPORT Human Clinical
"Among 12 IDH2-mutated cases in cohort 1, five (41.7%) harboured co-existing TP53 mutations, four (33.3%) CDKN2A/2B loss-of-function alterations, four (33.3%) MYC amplification, and three (25%) had concurrent SETD2 mutations."
Quantifies co-occurring TP53 mutation within IDH2-mutant SNUC.
CDKN2A (Co-occurring somatic loss-of-function)
Gene: CDKN2A hgnc:1787 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CDKN2A (hgnc:1787). hgnc:1787 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:28493366 SUPPORT Human Clinical
"Among 12 IDH2-mutated cases in cohort 1, five (41.7%) harboured co-existing TP53 mutations, four (33.3%) CDKN2A/2B loss-of-function alterations, four (33.3%) MYC amplification, and three (25%) had concurrent SETD2 mutations."
Quantifies co-occurring CDKN2A/2B loss-of-function within IDH2-mutant SNUC.
KIT (Co-occurring somatic activating mutation)
Gene: KIT hgnc:6342 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is KIT (hgnc:6342). hgnc:6342 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
DOI:10.1097/PAS.0000000000001064 SUPPORT Human Clinical
"IDH-mutant carcinomas also had frequent mutations in TP53 (55%) and activating mutations in KIT (45%) or the PI3K pathway (36%)."
Establishes recurrent activating KIT mutation as part of the co-alteration spectrum accompanying the IDH2 driver in sinonasal carcinoma.
💊

Medical Actions

4
Induction Chemotherapy
Action: chemotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is chemotherapy (NCIT:C15632). NCIT:C15632 is a clinical intervention from the NCI Thesaurus. Ontology label: Chemotherapy NCIT:C15632
Induction chemotherapy before definitive locoregional therapy is both treatment and a biological test. In a 95-patient single-institution cohort the 5-year disease-specific survival was 59% overall; among responders, definitive chemoradiotherapy outperformed surgery, while among non-responders the position reversed and definitive chemoradiotherapy was associated with 0% 5-year disease-specific survival.
Show evidence (2 references)
PMID:30615549 SUPPORT Human Clinical
"In patients who achieve a favorable response to IC, definitive CRT results in improved survival compared with those who undergo definitive surgery."
Supports induction chemotherapy response as the discriminator that selects the definitive modality.
PMID:30615549 SUPPORT Human Clinical
"For the entire cohort, the 5-years DSS probability was 59% (95% CI, 53% to 66%)."
Gives the cohort-level survival benchmark against which the response-stratified arms are read.
Definitive Chemoradiotherapy
Action: Radiation TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Radiation Therapy (NCIT:C15313). NCIT:C15313 is a clinical intervention from the NCI Thesaurus. NCIT:C15313
Concurrent chemoradiotherapy after induction chemotherapy is the preferred definitive modality in patients achieving at least a partial response, with a 5-year disease-specific survival of 81% in that group.
Show evidence (1 reference)
PMID:30615549 SUPPORT Human Clinical
"In patients who had partial or complete response to IC, the 5-year DSS probabilities were 81% (95% CI, 69% to 88%) after treatment with definitive concurrent chemoradiotherapy (CRT) after IC"
Quantifies the survival achieved with definitive chemoradiotherapy in induction-chemotherapy responders.
Surgical Resection
Action: surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surgical procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Surgery, with postoperative radiotherapy or chemoradiotherapy, is the better option for patients who do not respond to induction chemotherapy, in whom definitive chemoradiotherapy performed markedly worse.
Show evidence (1 reference)
PMID:30615549 SUPPORT Human Clinical
"In patients who do not achieve a favorable response to IC, surgery when feasible seems to provide a better chance of disease control and improved survival."
Supports surgery as the preferred definitive modality in induction-chemotherapy non-responders.
IDH2-Targeted Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: enasidenib CHEBI:145374 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses enasidenib (CHEBI:145374). CHEBI:145374 is a therapeutic agent from Chemical Entities of Biological Interest.
Because the IDH2 R172 hotspot is present in the large majority of SNUCs and is a druggable neomorphic enzyme, mutant-IDH2 inhibition has been proposed as a targeted strategy. It has reached prospective testing: NCT06176989 is an open NCI phase II of enasidenib in IDH2-mutated sinonasal and skull-base tumors, SNUC among them. No efficacy results are yet reported, so what is curated here remains a mechanistic rationale drawn from the genomic series rather than a demonstrated benefit.
Mechanism Target:
INHIBITS IDH2 R172 Neomorphic Hotspot Mutation — Mutant-selective IDH2 inhibition is directed at the neomorphic enzyme activity modeled by this node.
Show evidence (1 reference)
PMID:28493366 SUPPORT Human Clinical
"The vast majority of SNUCs and variable proportions of other poorly-differentiated sinonasal carcinomas may be amenable to IDH2-targeted therapy."
Supports the target relationship only. Amenability is inferred from mutation frequency and no treatment outcomes are reported, so this edge is a mechanistic rationale rather than an efficacy claim.
Show evidence (1 reference)
PMID:28493366 SUPPORT Human Clinical
"The vast majority of SNUCs and variable proportions of other poorly-differentiated sinonasal carcinomas may be amenable to IDH2-targeted therapy."
Supports the target rationale only. The authors state amenability inferred from mutation frequency; they report no treatment outcomes, so this is recorded as PARTIAL rather than SUPPORT.
🔬

Diagnosis

4
Endoscopic Biopsy
Nasal endoscopy with biopsy establishes the histologic diagnosis and excludes the morphologic mimics (olfactory neuroblastoma, rhabdomyosarcoma, lymphoma, melanoma, neuroendocrine carcinoma).
biopsy procedure NCIT:C15189 NCI Thesaurus (NCIT)
Mutant-Specific IDH1/2 Immunohistochemistry
Multispecific mutant IDH1/2 immunohistochemistry detects the R132/R172 mutant protein product. It is a rule-in test rather than a rule-out one: in the largest cohort staining was absent in all 132 histologic mimics (specificity 100%) but positive in only 26 of 53 SNUCs (49%), because the antibody does not recognise the full range of IDH alleles. A negative stain therefore does not exclude an IDH2-mutant SNUC and sequencing remains necessary to rule the diagnosis out.
diagnostic procedure NCIT:C18020 NCI Thesaurus (NCIT)
The allele dependence is what limits sensitivity rather than assay quality: in the same cohort every strongly staining case carried IDH2 R172S/G, the weakly staining cases all carried R172T, and sequencing of IHC-negative cases still recovered an IDH2 R172T and an IDH1 R132C. The two positive series are consistent once read this way, and the earlier 3/3-positive report is a small-sample view of the strongly staining alleles.
Show evidence (3 references)
PMID:28084339 SUPPORT Human Clinical
"Multispecific mutant IDH1/2 immunohistochemistry was performed and identified mutant-specific protein expression in all cases with available tissue: 3/3 sinonasal undifferentiated carcinomas with R172 mutations were positive and 4/4 wild-type cases were negative."
Supports mutant-specific IHC as a concordant surrogate for IDH2 R172 genotype, though on very small numbers.
DOI:10.1097/PAS.0000000000001064 SUPPORT Human Clinical
"Mutant IDH1/2 IHC was positive in 26/53 SNUCs (49%; 20 strongly positive and 6 weak) and 3/8 PDCARs (37.5%; 2 strong; 1 weak) but was absent in all other tumor types (0/132)."
In a 193-tumor cohort, mutant-specific IHC is perfectly specific against the histologic mimics but only about half sensitive within SNUC. Recorded as PARTIAL because it supports IHC as a rule-in test while refuting the stronger reading that a negative stain excludes an IDH2-mutant SNUC.
DOI:10.1097/PAS.0000000000001064 SUPPORT Human Clinical
"Mutation-specific IDH1/2 IHC identifies IDH mutations in SNUC, however, it lacks sensitivity for the full range of IDH mutations."
The authors' own statement of the sensitivity ceiling, which is why the description no longer presents IHC as a substitute for sequencing.
DNA Methylation Profiling
Genome-wide methylation profiling clusters IDH2-mutant sinonasal carcinomas together and separates them from SMARCB1-deficient carcinoma and olfactory neuroblastoma, improving classification of this diagnostically difficult group.
diagnostic procedure NCIT:C18020 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:31186531 SUPPORT Human Clinical
"t-distributed stochastic neighbor embedding dimensionality reduction analysis showed no overlap between IDH2 mutants, SMARCB1-deficient carcinoma and olfactory neuroblastoma."
Supports methylation profiling as a discriminator between SNUC and its principal diagnostic mimics.
CT and MRI Staging
Cross-sectional imaging defines orbital, cribriform-plate, and anterior skull-base extension, which drives the choice between definitive chemoradiotherapy and surgery.
magnetic resonance imaging NCIT:C16809 NCI Thesaurus (NCIT)
📊

Prevalence

1
United States (SEER registry, 1973-2011)
Cases In Literature Ultra Rare
Registry-ascertained case count rather than a rate: the SEER database yielded only 328 SNUC cases across 38 years of national cancer-registry coverage, which is why almost all SNUC evidence comes from single-institution series and pooled registry analyses rather than trials. No SNUC-specific incidence rate is quoted here because the cited analysis reports the cohort size, not a denominator-based rate.
Show evidence (1 reference)
PMID:26908559 SUPPORT Human Clinical
"The SEER registry was utilized to calculate survival trends for 328 patients with SNUC between 1973 and 2011."
Gives the total SNUC case count ascertained by a national cancer registry over 38 years, establishing the order of magnitude of the disease's rarity.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Sinonasal Undifferentiated Carcinoma:

Olfactory Neuroblastoma Not Yet Curated MONDO:0006329
Overlapping Features Esthesioneuroblastoma arises from olfactory neuroepithelium at the cribriform plate and overlaps SNUC in site, stage at presentation, and small-blue-cell morphology, but is IDH2-wild-type and separates cleanly from SNUC on genome-wide DNA methylation profiling.
Distinguishing Features
  • IDH2 R172 wild type
  • Distinct DNA-methylation class with no overlap against IDH2-mutant sinonasal carcinomas on dimensionality-reduction analysis
Show evidence (1 reference)
PMID:31186531 SUPPORT Human Clinical
"t-distributed stochastic neighbor embedding dimensionality reduction analysis showed no overlap between IDH2 mutants, SMARCB1-deficient carcinoma and olfactory neuroblastoma."
Demonstrates that olfactory neuroblastoma forms a methylation class separate from IDH2-mutant SNUC, which is what makes it a resolvable differential rather than a morphologic tie.
SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma
Overlapping Features A separately recognized sinonasal entity defined by loss of SMARCB1/INI-1, historically diagnosed as SNUC before INI-1 immunohistochemistry became routine. It is IDH2-wild-type, forms its own DNA-methylation class, and carries a worse prognosis and higher locoregional recurrence rate than SNUC, so the distinction changes prognostic counselling rather than being purely academic.
Distinguishing Features
  • Loss of SMARCB1/INI-1 nuclear expression by immunohistochemistry
  • IDH2 R172 wild type
  • Separate DNA-methylation class
Show evidence (2 references)
PMID:32001406 SUPPORT Human Clinical
"Studies comparing sinonasal undifferentiated carcinoma to SDSC reported worse prognosis for SDSC and increased risk for locoregional recurrence in the latter cohort."
Establishes that SMARCB1-deficient sinonasal carcinoma behaves differently from SNUC, which is why it must be excluded rather than lumped with it.
DOI:10.1007/s12105-022-01416-x SUPPORT Human Clinical
"Notably, all studied cases lacked oncogenic IDH2 mutations characteristic of genuine SNUC."
Confirms the genotypic separation this differential rests on: the SWI/SNF-deficient sinonasal carcinomas are IDH2-wild-type, so the IDH2 R172 hotspot discriminates them from SNUC rather than merely correlating.
🔬

Clinical Trials

2
NCT06176989 PHASE_II RECRUITING
NCI single-arm phase II of oral enasidenib, a mutant-selective IDH2 inhibitor, in IDH2-mutated malignant sinonasal and skull-base tumors that have recurred locally or metastasized. Eligible histologies include sinonasal undifferentiated carcinoma. This is the prospective test of the IDH2-Targeted Therapy rationale curated above.
Target Phenotypes: Paranasal sinus neoplasm HP:0030072 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Paranasal sinus neoplasm (HP:0030072). HP:0030072 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT06176989 SUPPORT Human Clinical
"Their cancer must have an IDH2 gene mutation, and it must have recurred locally or spread to other parts of the body. These cancers can include sinonasal undifferentiated carcinoma"
Establishes that mutant-IDH2 inhibition is under prospective evaluation in SNUC specifically, which is why the treatment description no longer says no controlled trial evidence exists.
NCT05925491 PHASE_II RECRUITING
Phase II of neoadjuvant pembrolizumab added to induction chemotherapy in locally advanced sinonasal undifferentiated carcinoma. It tests whether checkpoint blockade can preserve the outcomes already achieved by induction chemotherapy while reducing treatment burden, so it sits alongside the Induction Chemotherapy entry rather than replacing it.
Target Phenotypes: Paranasal sinus neoplasm HP:0030072 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Paranasal sinus neoplasm (HP:0030072). HP:0030072 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT05925491 SUPPORT Human Clinical
"This study will test the Safety and activity of pembrolizumab plus chemotherapy as neoadjuvant treatment in locally advanced sinonasal undifferentiated carcinoma (SNUC)."
Establishes the trial's population and intervention as SNUC-specific neoadjuvant chemoimmunotherapy.
{ }

Source YAML

click to show 
name: Sinonasal Undifferentiated Carcinoma
creation_date: "2026-08-27T00:00:00Z"
description: >-
  Sinonasal undifferentiated carcinoma (SNUC) is a rare, high-grade epithelial
  malignancy of the nasal cavity and paranasal sinuses, defined by an
  undifferentiated morphology with no squamous or glandular differentiation and
  no evidence of Epstein-Barr virus association. It was long a diagnosis of
  exclusion, but molecular profiling has established a dominant driver: a
  neomorphic IDH2 R172 hotspot mutation, reported in 55% to more than 80% of
  cases, which produces a global DNA and H3K27 hypermethylator phenotype and
  segregates SNUC (together with IDH2-mutant large cell neuroendocrine
  carcinoma) from its histologic mimics — olfactory neuroblastoma,
  SMARCB1-deficient sinonasal carcinoma, and small cell neuroendocrine
  carcinoma. IDH2-wild-type tumors instead carry SMARCA4, NOTCH1, or TET2
  alterations. Cooperating TP53 mutation and CDKN2A/2B loss are frequent within
  IDH2-mutant tumors. Clinically SNUC presents late with bulky disease invading
  the orbit and anterior skull base, and outcome depends heavily on response to
  induction chemotherapy, which is used both as therapy and as a biological
  test to select between definitive chemoradiotherapy and surgery.
categories:
- Head and Neck Cancer
- Rare Cancer
- Solid Tumor
disease_term:
  preferred_term: sinonasal undifferentiated carcinoma
  term:
    id: MONDO:0006411
    label: sinonasal undifferentiated carcinoma
synonyms:
- SNUC
- sinonasal anaplastic carcinoma
- undifferentiated sinonasal carcinoma
parents:
- undifferentiated carcinoma
notes: >-
  MONDO classifies this entity only under undifferentiated carcinoma
  (MONDO:0005617) and not under the sinonasal/paranasal site branch, so it is
  not a MONDO descendant of paranasal sinus carcinoma (MONDO:0000380) even
  though the tumor is defined by that anatomic origin. The curated grouping
  Paranasal_Sinus_Carcinoma records the site-based membership that MONDO does
  not assert.
pathophysiology:
- name: IDH2 R172 Neomorphic Hotspot Mutation
  biological_scale: MOLECULAR
  description: >-
    A somatic hotspot substitution at IDH2 residue R172 (R172S, R172T, R172M,
    and related variants) converts isocitrate dehydrogenase 2 into a neomorphic
    enzyme. This is the single most frequent recurrent alteration in SNUC,
    detected in 55% of cases in one targeted-sequencing series and in 82.4% in
    another, and it is essentially absent from the other head and neck tumor
    types tested. Mutant-specific IDH1/2 immunohistochemistry tracks the
    mutation, making it a practical diagnostic surrogate.
  cell_types:
  - preferred_term: sinonasal epithelial cell
    term:
      id: CL:0000066
      label: epithelial cell
  locations:
  - preferred_term: paranasal sinus
    term:
      id: UBERON:0001825
      label: paranasal sinus
  molecular_functions:
  - preferred_term: isocitrate dehydrogenase (NADP+) activity
    modifier: GAIN_OF_FUNCTION
    term:
      id: GO:0004450
      label: isocitrate dehydrogenase (NADP+) activity
  downstream:
  - target: DNA and Histone Hypermethylator Phenotype
    description: >-
      Neomorphic IDH2 activity drives the global methylation phenotype that
      distinguishes IDH2-mutant sinonasal carcinomas.
  evidence:
  - reference: PMID:28084339
    reference_title: Recurrent IDH2 R172X mutations in sinonasal undifferentiated
      carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified IDH2 R172X mutations in 55% of sinonasal undifferentiated
      carcinomas including R172S, R172T, and R172M.
    explanation: >-
      Establishes IDH2 R172 hotspot substitution as a recurrent somatic driver
      in SNUC and names the specific residue changes.
  - reference: PMID:28493366
    reference_title: Frequent IDH2 R172 mutations in undifferentiated and
      poorly-differentiated sinonasal carcinomas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      IDH2 R172 single nucleotide variants were overall detected in 14 (82.4%)
      SNUCs
    explanation: >-
      Independent cohort giving a higher hotspot frequency, supporting IDH2 R172
      mutation as the dominant molecular event rather than an incidental finding.
- name: DNA and Histone Hypermethylator Phenotype
  biological_scale: MOLECULAR
  description: >-
    Mutant IDH2 induces a global hypermethylator state: genome-wide DNA
    methylation profiling separates IDH2-mutant sinonasal tumors into a single
    cluster irrespective of histologic type, and the tumors show increased
    repressive H3K27 trimethylation relative to IDH2-wild-type tumors. This
    epigenetic reprogramming, rather than a proliferative signaling lesion, is
    the proximate consequence of the driver mutation.
  cell_types:
  - preferred_term: sinonasal epithelial cell
    term:
      id: CL:0000066
      label: epithelial cell
  biological_processes:
  - preferred_term: negative regulation of gene expression via chromosomal CpG island
      methylation
    modifier: INCREASED
    term:
      id: GO:0044027
      label: negative regulation of gene expression via chromosomal CpG island methylation
  downstream:
  - target: Undifferentiated High-Grade Proliferation
    description: >-
      Widespread promoter and H3K27 hypermethylation is proposed to lock the
      sinonasal epithelium out of a differentiated program, leaving a
      high-grade undifferentiated tumor cell.
  evidence:
  - reference: PMID:31186531
    reference_title: DNA methylation-based classification of sinonasal undifferentiated
      carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      IDH2 mutations in sinonasal carcinomas induce a hypermethylator phenotype
      and define a molecular subgroup of tumors arising in this location.
    explanation: >-
      States directly that the IDH2 mutation induces the hypermethylator
      phenotype modeled by this node.
  - reference: PMID:31186531
    reference_title: DNA methylation-based classification of sinonasal undifferentiated
      carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      IDH2 mutants demonstrated a global methylation phenotype and an increase in
      repressive trimethylation of H3K27 in comparison to IDH2 wild-type tumors
      (p < 0.001).
    explanation: >-
      Quantifies both the DNA-methylation and the repressive histone-methylation
      arms of this node against an IDH2-wild-type comparator.
- name: Cooperating Tumor Suppressor Loss
  biological_scale: MOLECULAR
  conforms_to: "evading_growth_suppressors#Tumor Suppressor Inactivation"
  description: >-
    IDH2 mutation alone is not sufficient. Within IDH2-mutant SNUC, co-occurring
    TP53 mutation and CDKN2A/2B loss-of-function alterations are each present in
    roughly a third to two fifths of cases, disabling the p53 and RB
    antiproliferative axes. IDH2-wild-type tumors reach a comparable end by a
    different route, through SMARCA4 loss-of-function with confirmed loss of
    protein expression, NOTCH1 gain-of-function, or TET2 loss-of-function.
  cell_types:
  - preferred_term: sinonasal epithelial cell
    term:
      id: CL:0000066
      label: epithelial cell
  biological_processes:
  - preferred_term: signal transduction by p53 class mediator
    modifier: DECREASED
    term:
      id: GO:0072331
      label: signal transduction by p53 class mediator
  - preferred_term: chromatin remodeling
    modifier: DECREASED
    term:
      id: GO:0006338
      label: chromatin remodeling
  downstream:
  - target: Undifferentiated High-Grade Proliferation
    description: >-
      Loss of the p53 and RB brakes, or of SWI/SNF chromatin-remodeling
      function, removes the antiproliferative control that would otherwise limit
      outgrowth of the transformed clone.
  evidence:
  - reference: PMID:28493366
    reference_title: Frequent IDH2 R172 mutations in undifferentiated and
      poorly-differentiated sinonasal carcinomas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among 12 IDH2-mutated cases in cohort 1, five (41.7%) harboured
      co-existing TP53 mutations, four (33.3%) CDKN2A/2B loss-of-function
      alterations, four (33.3%) MYC amplification, and three (25%) had
      concurrent SETD2 mutations.
    explanation: >-
      Quantifies co-occurring TP53 and CDKN2A/2B inactivation within
      IDH2-mutant SNUC, which is what this node claims and what grounds the
      conformance to the evading_growth_suppressors trigger.
  - reference: PMID:28084339
    reference_title: Recurrent IDH2 R172X mutations in sinonasal undifferentiated
      carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Alterations in the IDH2-wild-type sinonasal undifferentiated carcinomas
      included SMARCA4 loss-of-function with confirmed loss of
      immunohistochemical expression, NOTCH1 gain-of-function, and TET2
      loss-of-function.
    explanation: >-
      Supports the alternative, IDH2-wild-type route to loss of growth
      suppression through SWI/SNF (SMARCA4) and TET2 inactivation.
- name: Undifferentiated High-Grade Proliferation
  biological_scale: CELLULAR
  description: >-
    The resulting tumor cell is undifferentiated and highly proliferative:
    cohesive nests, ribbons, and trabeculae of cells with hyperchromatic nuclei
    and a high nuclear-to-cytoplasmic ratio, a brisk mitotic rate, tumor
    necrosis, and vascular invasion. The absence of squamous or glandular
    differentiation is definitional and is what historically made SNUC a
    diagnosis of exclusion.
  cell_types:
  - preferred_term: sinonasal epithelial cell
    term:
      id: CL:0000066
      label: epithelial cell
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  downstream:
  - target: Rapid Local Invasion of Orbit and Anterior Skull Base
    description: >-
      Rapid, poorly differentiated growth in an anatomically unconfined
      air-filled space produces early transgression of the sinus walls.
  evidence:
  - reference: PMID:10562893
    reference_title: "Sinonasal undifferentiated carcinoma: a distinctive
      clinicopathologic entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A brisk mitotic rate, tumor necrosis, and vascular invasion are prominent
      features.
    explanation: >-
      Describes the high-grade proliferative and necrotic phenotype this node
      models.
- name: Rapid Local Invasion of Orbit and Anterior Skull Base
  biological_scale: TISSUE
  description: >-
    Because the paranasal sinuses are air-filled spaces that produce few early
    symptoms, SNUC characteristically reaches the orbit, cribriform plate, and
    anterior cranial fossa before diagnosis. Advanced stage at presentation,
    high locoregional recurrence, and a tendency to metastasize together account
    for the poor prognosis.
  locations:
  - preferred_term: paranasal sinus
    term:
      id: UBERON:0001825
      label: paranasal sinus
  evidence:
  - reference: PMID:30806835
    reference_title: Sinonasal Undifferentiated Carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SNUC usually presents at advanced stage and the prognosis is usually poor
      with high rates of locoregional recurrence and tendency to metastasize.
    explanation: >-
      Supports advanced-stage local disease with high locoregional recurrence as
      the dominant clinical behavior of SNUC.
histopathology:
- name: Nuclear Pleomorphism
  finding_term:
    preferred_term: Nuclear Pleomorphism
    term:
      id: NCIT:C38721
      label: Nuclear Pleomorphism
  diagnostic: true
  description: >-
    Cohesive cells with hyperchromatic nuclei and a high nuclear-to-cytoplasmic
    ratio arranged in nests, ribbons, and trabeculae.
  evidence:
  - reference: PMID:10562893
    reference_title: "Sinonasal undifferentiated carcinoma: a distinctive
      clinicopathologic entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The cells exhibit hyperchromatic nuclei and a high nuclear to cytoplasmic
      ratio.
    explanation: >-
      Describes the nuclear morphology recorded by this finding.
- name: Increased Mitotic Activity
  finding_term:
    preferred_term: Increased Mitotic Activity
    term:
      id: NCIT:C163732
      label: Increased Mitotic Activity
  description: >-
    A brisk mitotic rate is a prominent and expected feature of this high-grade
    carcinoma.
  evidence:
  - reference: PMID:10562893
    reference_title: "Sinonasal undifferentiated carcinoma: a distinctive
      clinicopathologic entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A brisk mitotic rate, tumor necrosis, and vascular invasion are prominent
      features.
    explanation: >-
      Names brisk mitotic activity as a prominent histologic feature.
- name: Tumor Cell Necrosis
  finding_term:
    preferred_term: Tumor Cell Necrosis
    term:
      id: NCIT:C35957
      label: Tumor Cell Necrosis
  description: >-
    Tumor necrosis accompanies the high proliferative rate and helps separate
    SNUC from lower-grade sinonasal mimics.
  evidence:
  - reference: PMID:10562893
    reference_title: "Sinonasal undifferentiated carcinoma: a distinctive
      clinicopathologic entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A brisk mitotic rate, tumor necrosis, and vascular invasion are prominent
      features.
    explanation: >-
      Names tumor necrosis as a prominent histologic feature.
phenotypes:
- category: Head and Neck
  name: Nasal Obstruction
  description: >-
    Unilateral nasal obstruction as the expanding tumor fills the nasal cavity
    and sinus.
  phenotype_term:
    preferred_term: Nasal obstruction
    term:
      id: HP:0001742
      label: Nasal congestion
  evidence:
  - reference: PMID:10562893
    reference_title: "Sinonasal undifferentiated carcinoma: a distinctive
      clinicopathologic entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Presenting symptoms include facial pain, nasal obstruction, diplopia,
      epistaxis, proptosis, and periorbital swelling.
    explanation: >-
      Lists nasal obstruction among the presenting symptoms of SNUC.
- category: Head and Neck
  name: Epistaxis
  description: Nosebleeds from an ulcerated, friable, highly vascular tumor surface.
  phenotype_term:
    preferred_term: Epistaxis
    term:
      id: HP:0000421
      label: Epistaxis
  evidence:
  - reference: PMID:10562893
    reference_title: "Sinonasal undifferentiated carcinoma: a distinctive
      clinicopathologic entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Presenting symptoms include facial pain, nasal obstruction, diplopia,
      epistaxis, proptosis, and periorbital swelling.
    explanation: >-
      Lists epistaxis among the presenting symptoms of SNUC.
- category: Ophthalmologic
  name: Proptosis
  description: >-
    Forward displacement of the globe once the tumor breaches the medial or
    inferior orbital wall.
  phenotype_term:
    preferred_term: Proptosis
    term:
      id: HP:0000520
      label: Proptosis
  evidence:
  - reference: PMID:10562893
    reference_title: "Sinonasal undifferentiated carcinoma: a distinctive
      clinicopathologic entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Presenting symptoms include facial pain, nasal obstruction, diplopia,
      epistaxis, proptosis, and periorbital swelling.
    explanation: >-
      Lists proptosis among the presenting symptoms of SNUC.
- category: Ophthalmologic
  name: Diplopia
  description: >-
    Double vision from orbital invasion and restriction or displacement of the
    extraocular muscles.
  phenotype_term:
    preferred_term: Diplopia
    term:
      id: HP:0000651
      label: Diplopia
  evidence:
  - reference: PMID:10562893
    reference_title: "Sinonasal undifferentiated carcinoma: a distinctive
      clinicopathologic entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Presenting symptoms include facial pain, nasal obstruction, diplopia,
      epistaxis, proptosis, and periorbital swelling.
    explanation: >-
      Lists diplopia among the presenting symptoms of SNUC.
- category: Neurologic
  name: Facial Pain
  description: >-
    Facial pain from tumor expansion within, and erosion of, the sinus walls.
  phenotype_term:
    preferred_term: Facial pain
    term:
      id: HP:0012531
      label: Pain
  notes: >-
    HP has no dedicated facial-pain class, so this is bound to the generic Pain
    term with a more specific preferred_term.
  evidence:
  - reference: PMID:10562893
    reference_title: "Sinonasal undifferentiated carcinoma: a distinctive
      clinicopathologic entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Presenting symptoms include facial pain, nasal obstruction, diplopia,
      epistaxis, proptosis, and periorbital swelling.
    explanation: >-
      Lists facial pain among the presenting symptoms of SNUC.
genetic:
- name: IDH2
  association: Somatic hotspot mutation
  gene_term:
    preferred_term: IDH2
    term:
      id: hgnc:5383
      label: IDH2
  notes: >-
    R172 hotspot substitutions (R172S, R172T, R172M and related variants).
    Reported in 55% of SNUCs in one series and 82.4% in another; the mutation is
    detectable by mutant-specific IDH1/2 immunohistochemistry.
  evidence:
  - reference: PMID:28084339
    reference_title: Recurrent IDH2 R172X mutations in sinonasal undifferentiated
      carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified IDH2 R172X mutations in 55% of sinonasal undifferentiated
      carcinomas including R172S, R172T, and R172M.
    explanation: >-
      Primary report of the recurrent IDH2 R172 hotspot in SNUC.
- name: SMARCA4
  association: Somatic loss-of-function
  gene_term:
    preferred_term: SMARCA4
    term:
      id: hgnc:11100
      label: SMARCA4
  notes: >-
    Found in IDH2-wild-type SNUC, alongside NOTCH1 gain-of-function and TET2
    loss-of-function, defining a molecularly distinct minority.
  evidence:
  - reference: PMID:28084339
    reference_title: Recurrent IDH2 R172X mutations in sinonasal undifferentiated
      carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Alterations in the IDH2-wild-type sinonasal undifferentiated carcinomas
      included SMARCA4 loss-of-function with confirmed loss of
      immunohistochemical expression, NOTCH1 gain-of-function, and TET2
      loss-of-function.
    explanation: >-
      Supports SMARCA4 loss of function as a driver in the IDH2-wild-type
      subset, confirmed at the protein level.
- name: TP53
  association: Co-occurring somatic mutation
  gene_term:
    preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  evidence:
  - reference: PMID:28493366
    reference_title: Frequent IDH2 R172 mutations in undifferentiated and
      poorly-differentiated sinonasal carcinomas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among 12 IDH2-mutated cases in cohort 1, five (41.7%) harboured
      co-existing TP53 mutations, four (33.3%) CDKN2A/2B loss-of-function
      alterations, four (33.3%) MYC amplification, and three (25%) had
      concurrent SETD2 mutations.
    explanation: >-
      Quantifies co-occurring TP53 mutation within IDH2-mutant SNUC.
- name: CDKN2A
  association: Co-occurring somatic loss-of-function
  gene_term:
    preferred_term: CDKN2A
    term:
      id: hgnc:1787
      label: CDKN2A
  evidence:
  - reference: PMID:28493366
    reference_title: Frequent IDH2 R172 mutations in undifferentiated and
      poorly-differentiated sinonasal carcinomas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among 12 IDH2-mutated cases in cohort 1, five (41.7%) harboured
      co-existing TP53 mutations, four (33.3%) CDKN2A/2B loss-of-function
      alterations, four (33.3%) MYC amplification, and three (25%) had
      concurrent SETD2 mutations.
    explanation: >-
      Quantifies co-occurring CDKN2A/2B loss-of-function within IDH2-mutant SNUC.
- name: KIT
  association: Co-occurring somatic activating mutation
  gene_term:
    preferred_term: KIT
    term:
      id: hgnc:6342
      label: KIT
  notes: >-
    Reported in 45% of IDH-mutant sinonasal carcinomas sequenced by targeted
    NGS, alongside TP53 (55%) and PI3K-pathway activating mutations (36%). The
    series does not report whether these are subclonal or whether the
    corresponding pathways are activated at the protein level, so no
    pathophysiology node is asserted for them here.
  evidence:
  - reference: DOI:10.1097/PAS.0000000000001064
    reference_title: Immunohistochemical Detection and Molecular Characterization
      of IDH-mutant Sinonasal Undifferentiated Carcinomas
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      IDH-mutant carcinomas also had frequent mutations in TP53 (55%) and
      activating mutations in KIT (45%) or the PI3K pathway (36%).
    explanation: >-
      Establishes recurrent activating KIT mutation as part of the co-alteration
      spectrum accompanying the IDH2 driver in sinonasal carcinoma.
treatments:
- name: Induction Chemotherapy
  description: >-
    Induction chemotherapy before definitive locoregional therapy is both
    treatment and a biological test. In a 95-patient single-institution cohort
    the 5-year disease-specific survival was 59% overall; among responders,
    definitive chemoradiotherapy outperformed surgery, while among
    non-responders the position reversed and definitive chemoradiotherapy was
    associated with 0% 5-year disease-specific survival.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
  evidence:
  - reference: PMID:30615549
    reference_title: Induction Chemotherapy Response as a Guide for Treatment
      Optimization in Sinonasal Undifferentiated Carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In patients who achieve a favorable response to IC, definitive CRT results
      in improved survival compared with those who undergo definitive surgery.
    explanation: >-
      Supports induction chemotherapy response as the discriminator that selects
      the definitive modality.
  - reference: PMID:30615549
    reference_title: Induction Chemotherapy Response as a Guide for Treatment
      Optimization in Sinonasal Undifferentiated Carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For the entire cohort, the 5-years DSS probability was 59% (95% CI, 53% to
      66%).
    explanation: >-
      Gives the cohort-level survival benchmark against which the
      response-stratified arms are read.
- name: Definitive Chemoradiotherapy
  description: >-
    Concurrent chemoradiotherapy after induction chemotherapy is the preferred
    definitive modality in patients achieving at least a partial response, with
    a 5-year disease-specific survival of 81% in that group.
  therapeutic_modality: RADIOTHERAPY
  treatment_term:
    preferred_term: Radiation Therapy
    term:
      id: NCIT:C15313
      label: Radiation Therapy
  evidence:
  - reference: PMID:30615549
    reference_title: Induction Chemotherapy Response as a Guide for Treatment
      Optimization in Sinonasal Undifferentiated Carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In patients who had partial or complete response to IC, the 5-year DSS
      probabilities were 81% (95% CI, 69% to 88%) after treatment with definitive
      concurrent chemoradiotherapy (CRT) after IC
    explanation: >-
      Quantifies the survival achieved with definitive chemoradiotherapy in
      induction-chemotherapy responders.
- name: Surgical Resection
  description: >-
    Surgery, with postoperative radiotherapy or chemoradiotherapy, is the better
    option for patients who do not respond to induction chemotherapy, in whom
    definitive chemoradiotherapy performed markedly worse.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:30615549
    reference_title: Induction Chemotherapy Response as a Guide for Treatment
      Optimization in Sinonasal Undifferentiated Carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In patients who do not achieve a favorable response to IC, surgery when
      feasible seems to provide a better chance of disease control and improved
      survival.
    explanation: >-
      Supports surgery as the preferred definitive modality in
      induction-chemotherapy non-responders.
- name: IDH2-Targeted Therapy
  description: >-
    Because the IDH2 R172 hotspot is present in the large majority of SNUCs and
    is a druggable neomorphic enzyme, mutant-IDH2 inhibition has been proposed
    as a targeted strategy. It has reached prospective testing: NCT06176989 is
    an open NCI phase II of enasidenib in IDH2-mutated sinonasal and skull-base
    tumors, SNUC among them. No efficacy results are yet reported, so what is
    curated here remains a mechanistic rationale drawn from the genomic series
    rather than a demonstrated benefit.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: enasidenib
      term:
        id: CHEBI:145374
        label: enasidenib
  target_mechanisms:
  - target: IDH2 R172 Neomorphic Hotspot Mutation
    treatment_effect: INHIBITS
    description: >-
      Mutant-selective IDH2 inhibition is directed at the neomorphic enzyme
      activity modeled by this node.
    evidence:
    - reference: PMID:28493366
      reference_title: Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated
        sinonasal carcinomas.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The vast majority of SNUCs and variable proportions of other
        poorly-differentiated sinonasal carcinomas may be amenable to
        IDH2-targeted therapy.
      explanation: >-
        Supports the target relationship only. Amenability is inferred from
        mutation frequency and no treatment outcomes are reported, so this edge is
        a mechanistic rationale rather than an efficacy claim.
  evidence:
  - reference: PMID:28493366
    reference_title: Frequent IDH2 R172 mutations in undifferentiated and
      poorly-differentiated sinonasal carcinomas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The vast majority of SNUCs and variable proportions of other
      poorly-differentiated sinonasal carcinomas may be amenable to
      IDH2-targeted therapy.
    explanation: >-
      Supports the target rationale only. The authors state amenability inferred
      from mutation frequency; they report no treatment outcomes, so this is
      recorded as PARTIAL rather than SUPPORT.
clinical_trials:
- name: NCT06176989
  phase: PHASE_II
  status: RECRUITING
  description: >-
    NCI single-arm phase II of oral enasidenib, a mutant-selective IDH2
    inhibitor, in IDH2-mutated malignant sinonasal and skull-base tumors that
    have recurred locally or metastasized. Eligible histologies include
    sinonasal undifferentiated carcinoma. This is the prospective test of the
    IDH2-Targeted Therapy rationale curated above.
  target_phenotypes:
  - preferred_term: Paranasal sinus neoplasm
    term:
      id: HP:0030072
      label: Paranasal sinus neoplasm
  evidence:
  - reference: clinicaltrials:NCT06176989
    reference_title: Phase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal
      and Skull Base Tumors
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Their cancer must have an IDH2 gene mutation, and it must have recurred
      locally or spread to other parts of the body. These cancers can include
      sinonasal undifferentiated carcinoma
    explanation: >-
      Establishes that mutant-IDH2 inhibition is under prospective evaluation in
      SNUC specifically, which is why the treatment description no longer says
      no controlled trial evidence exists.
- name: NCT05925491
  phase: PHASE_II
  status: RECRUITING
  description: >-
    Phase II of neoadjuvant pembrolizumab added to induction chemotherapy in
    locally advanced sinonasal undifferentiated carcinoma. It tests whether
    checkpoint blockade can preserve the outcomes already achieved by induction
    chemotherapy while reducing treatment burden, so it sits alongside the
    Induction Chemotherapy entry rather than replacing it.
  target_phenotypes:
  - preferred_term: Paranasal sinus neoplasm
    term:
      id: HP:0030072
      label: Paranasal sinus neoplasm
  evidence:
  - reference: clinicaltrials:NCT05925491
    reference_title: Neoadjuvant Pembrolizumab Plus Chemotherapy in Locally Advanced
      Sinonasal Carcinoma
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study will test the Safety and activity of pembrolizumab plus
      chemotherapy as neoadjuvant treatment in locally advanced sinonasal
      undifferentiated carcinoma (SNUC).
    explanation: >-
      Establishes the trial's population and intervention as SNUC-specific
      neoadjuvant chemoimmunotherapy.
diagnosis:
- name: Endoscopic Biopsy
  description: >-
    Nasal endoscopy with biopsy establishes the histologic diagnosis and
    excludes the morphologic mimics (olfactory neuroblastoma, rhabdomyosarcoma,
    lymphoma, melanoma, neuroendocrine carcinoma).
  diagnosis_term:
    preferred_term: biopsy procedure
    term:
      id: NCIT:C15189
      label: Biopsy Procedure
- name: Mutant-Specific IDH1/2 Immunohistochemistry
  description: >-
    Multispecific mutant IDH1/2 immunohistochemistry detects the R132/R172
    mutant protein product. It is a rule-in test rather than a rule-out one:
    in the largest cohort staining was absent in all 132 histologic mimics
    (specificity 100%) but positive in only 26 of 53 SNUCs (49%), because the
    antibody does not recognise the full range of IDH alleles. A negative stain
    therefore does not exclude an IDH2-mutant SNUC and sequencing remains
    necessary to rule the diagnosis out.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  evidence:
  - reference: PMID:28084339
    reference_title: Recurrent IDH2 R172X mutations in sinonasal undifferentiated
      carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Multispecific mutant IDH1/2 immunohistochemistry was performed and
      identified mutant-specific protein expression in all cases with available
      tissue: 3/3 sinonasal undifferentiated carcinomas with R172 mutations were
      positive and 4/4 wild-type cases were negative.
    explanation: >-
      Supports mutant-specific IHC as a concordant surrogate for IDH2 R172
      genotype, though on very small numbers.
  - reference: DOI:10.1097/PAS.0000000000001064
    reference_title: Immunohistochemical Detection and Molecular Characterization
      of IDH-mutant Sinonasal Undifferentiated Carcinomas
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutant IDH1/2 IHC was positive in 26/53 SNUCs (49%; 20 strongly positive
      and 6 weak) and 3/8 PDCARs (37.5%; 2 strong; 1 weak) but was absent in all
      other tumor types (0/132).
    explanation: >-
      In a 193-tumor cohort, mutant-specific IHC is perfectly specific against
      the histologic mimics but only about half sensitive within SNUC. Recorded
      as PARTIAL because it supports IHC as a rule-in test while refuting the
      stronger reading that a negative stain excludes an IDH2-mutant SNUC.
  - reference: DOI:10.1097/PAS.0000000000001064
    reference_title: Immunohistochemical Detection and Molecular Characterization
      of IDH-mutant Sinonasal Undifferentiated Carcinomas
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutation-specific IDH1/2 IHC identifies IDH mutations in SNUC, however, it
      lacks sensitivity for the full range of IDH mutations.
    explanation: >-
      The authors' own statement of the sensitivity ceiling, which is why the
      description no longer presents IHC as a substitute for sequencing.
  notes: >-
    The allele dependence is what limits sensitivity rather than assay quality:
    in the same cohort every strongly staining case carried IDH2 R172S/G, the
    weakly staining cases all carried R172T, and sequencing of IHC-negative
    cases still recovered an IDH2 R172T and an IDH1 R132C. The two positive
    series are consistent once read this way, and the earlier 3/3-positive
    report is a small-sample view of the strongly staining alleles.
- name: DNA Methylation Profiling
  description: >-
    Genome-wide methylation profiling clusters IDH2-mutant sinonasal carcinomas
    together and separates them from SMARCB1-deficient carcinoma and olfactory
    neuroblastoma, improving classification of this diagnostically difficult
    group.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  evidence:
  - reference: PMID:31186531
    reference_title: DNA methylation-based classification of sinonasal undifferentiated
      carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      t-distributed stochastic neighbor embedding dimensionality reduction
      analysis showed no overlap between IDH2 mutants, SMARCB1-deficient
      carcinoma and olfactory neuroblastoma.
    explanation: >-
      Supports methylation profiling as a discriminator between SNUC and its
      principal diagnostic mimics.
- name: CT and MRI Staging
  description: >-
    Cross-sectional imaging defines orbital, cribriform-plate, and anterior
    skull-base extension, which drives the choice between definitive
    chemoradiotherapy and surgery.
  diagnosis_term:
    preferred_term: magnetic resonance imaging
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
prevalence:
- population: United States (SEER registry, 1973-2011)
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Registry-ascertained case count rather than a rate: the SEER database yielded
    only 328 SNUC cases across 38 years of national cancer-registry coverage,
    which is why almost all SNUC evidence comes from single-institution series
    and pooled registry analyses rather than trials. No SNUC-specific incidence
    rate is quoted here because the cited analysis reports the cohort size, not
    a denominator-based rate.
  evidence:
  - reference: PMID:26908559
    reference_title: "Significance of Tumor Stage in Sinonasal Undifferentiated Carcinoma Survival: A Population-Based Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The SEER registry was utilized to calculate survival trends for 328
      patients with SNUC between 1973 and 2011.
    explanation: >-
      Gives the total SNUC case count ascertained by a national cancer registry
      over 38 years, establishing the order of magnitude of the disease's rarity.
differential_diagnoses:
- name: Olfactory Neuroblastoma
  disease_term:
    preferred_term: olfactory neuroblastoma
    term:
      id: MONDO:0006329
      label: olfactory neuroblastoma
  description: >-
    Esthesioneuroblastoma arises from olfactory neuroepithelium at the cribriform
    plate and overlaps SNUC in site, stage at presentation, and small-blue-cell
    morphology, but is IDH2-wild-type and separates cleanly from SNUC on
    genome-wide DNA methylation profiling.
  distinguishing_features:
  - IDH2 R172 wild type
  - >-
    Distinct DNA-methylation class with no overlap against IDH2-mutant sinonasal
    carcinomas on dimensionality-reduction analysis
  evidence:
  - reference: PMID:31186531
    reference_title: "DNA methylation-based classification of sinonasal undifferentiated carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      t-distributed stochastic neighbor embedding dimensionality reduction
      analysis showed no overlap between IDH2 mutants, SMARCB1-deficient
      carcinoma and olfactory neuroblastoma.
    explanation: >-
      Demonstrates that olfactory neuroblastoma forms a methylation class
      separate from IDH2-mutant SNUC, which is what makes it a resolvable
      differential rather than a morphologic tie.
- name: SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma
  description: >-
    A separately recognized sinonasal entity defined by loss of SMARCB1/INI-1,
    historically diagnosed as SNUC before INI-1 immunohistochemistry became
    routine. It is IDH2-wild-type, forms its own DNA-methylation class, and
    carries a worse prognosis and higher locoregional recurrence rate than SNUC,
    so the distinction changes prognostic counselling rather than being purely
    academic.
  distinguishing_features:
  - Loss of SMARCB1/INI-1 nuclear expression by immunohistochemistry
  - IDH2 R172 wild type
  - Separate DNA-methylation class
  evidence:
  - reference: PMID:32001406
    reference_title: "SMARCB1-Deficient Sinonasal Carcinoma: Systematic Review and Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Studies comparing sinonasal undifferentiated carcinoma to SDSC reported
      worse prognosis for SDSC and increased risk for locoregional recurrence in
      the latter cohort.
    explanation: >-
      Establishes that SMARCB1-deficient sinonasal carcinoma behaves differently
      from SNUC, which is why it must be excluded rather than lumped with it.
  - reference: DOI:10.1007/s12105-022-01416-x
    reference_title: "Proceedings of the North American Society of Head and Neck
      Pathology, Los Angeles, CA, March 20, 2022: SWI/SNF-deficient Sinonasal
      Neoplasms: An Overview"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Notably, all studied cases lacked oncogenic IDH2 mutations characteristic
      of genuine SNUC.
    explanation: >-
      Confirms the genotypic separation this differential rests on: the
      SWI/SNF-deficient sinonasal carcinomas are IDH2-wild-type, so the IDH2
      R172 hotspot discriminates them from SNUC rather than merely correlating.
  notes: >-
    MONDO has no class for SMARCB1 (INI-1)-deficient sinonasal carcinoma, so
    this differential carries no disease_term. MONDO:0100534 is the renal
    medullary SMARCB1-deficient carcinoma and is a different entity.
datasets: []
📚

References & Deep Research

Deep Research

1
Falcon ▸
Sinonasal Undifferentiated Carcinoma: Disease Characteristics Report
Edison Scientific Literature 18 citations 2026-08-27T13:58:57.193078

Sinonasal Undifferentiated Carcinoma: Disease Characteristics Report

Target disease: Sinonasal undifferentiated carcinoma (SNUC)
Category: Rare, high-grade epithelial malignancy of the nasal cavity and paranasal sinuses
Evidence scope: Disease-level synthesis from peer-reviewed human studies and reviews, supplemented by interventional-trial records. It is not an individual-patient/EHR analysis. Because historical “SNUC” series included tumors now recognized as NUT carcinoma and SMARCB1- or SMARCA4-deficient carcinoma, older estimates require caution.

Executive summary

SNUC is a rapidly progressive, poorly differentiated carcinoma arising in the sinonasal tract. Modern pathology treats it as a diagnosis of exclusion, not a generic label for every undifferentiated sinonasal tumor. Genuine SNUC commonly carries a somatic IDH2 p.Arg172 hotspot mutation, whereas SWI/SNF-deficient sinonasal carcinomas are separate entities. Most patients present in the fifth to sixth decade with obstruction, epistaxis, headache, or visual symptoms and already have extensive local disease. Management is multidisciplinary and generally combines platinum-based chemotherapy, radiotherapy, and selected surgery. The strongest contemporary treatment-selection evidence supports using response to induction chemotherapy to guide definitive chemoradiation versus surgery. Prospective phase II studies are now testing pembrolizumab-containing induction therapy and enasidenib for IDH2-mutant recurrent or metastatic disease. (thawani2023thecontemporarymanagement pages 12-14, NCT05925491 chunk 1, thawani2023thecontemporarymanagement pages 14-15, NCT06176989 chunk 1, mito2018immunohistochemicaldetectionand pages 1-2, agaimy2022proceedingsofthe pages 1-2)

The principal quantitative findings are summarized below.

Domain Best-supported finding Quantitative data Evidence type/source year
Definition/classification Genuine SNUC is now treated as a diagnosis of exclusion among poorly differentiated sinonasal carcinomas and should be separated from SWI/SNF-deficient and NUT carcinomas. No single numeric metric; classification shift emphasized in modern reviews and pathology overviews. Review/pathology synthesis, 2022-2023 (thawani2023thecontemporarymanagement pages 14-15, agaimy2022proceedingsofthe pages 1-2)
Epidemiology SNUC is extremely rare and represents a small fraction of sinonasal malignancies. ~5% of sinonasal malignancies; annual incidence ~0.02/100,000/year; male incidence 0.03/100,000/year vs female 0.01/100,000/year; median age 50-60 years. Review summarizing SEER and prior series, 2023 (thawani2023thecontemporarymanagement pages 12-14)
Presentation at diagnosis Symptoms are nonspecific and advanced local disease is common. Nasal obstruction 20.0%; epistaxis 17.1%; diplopia/visual symptoms 15.0%; headache 12.1%; orbital involvement 42.9%; stage IV at diagnosis 72.9%. Review citing systematic/retrospective SNUC studies, 2023 (thawani2023thecontemporarymanagement pages 12-14)
Metastatic behavior SNUC has substantial regional and distant metastatic risk. Regional metastasis 5-16%; distant metastasis 20-30%; common sites include bone, cervical lymph nodes, lung, brain, liver. Review of primary SNUC literature, 2023 (thawani2023thecontemporarymanagement pages 12-14)
Pathology/IHC Typical phenotype supports epithelial differentiation but not specific lineage. Commonly positive/variable: AE1/AE3, CAM5.2, CK8, CK7/8/19; typically negative: S-100, CK5/6, p40, CD45, desmin, myogenin, MelanA, HMB45. Review plus multi-institutional pathology study, 2018-2023 (thawani2023thecontemporarymanagement pages 14-15, mito2018immunohistochemicaldetectionand pages 1-2)
Molecular genetics: IDH IDH2 hotspot mutation is the strongest recurrent molecular feature of genuine SNUC. IDH2-mutant frequency reported as 62.5% (10/16), 54.5% (6/11), and 82.4% (14/17) across cited SNUC series; multi-institutional cohort found mutant IDH1/2 IHC positive in 26/53 SNUC (49%), with NGS showing frequent IDH2 R172X and rare IDH1 R132C. Primary molecular pathology 2018 plus review 2023 (thawani2023thecontemporarymanagement pages 14-15, mito2018immunohistochemicaldetectionand pages 1-2)
Molecular co-alterations in IDH2-mutant SNUC Additional recurrent alterations occur but appear secondary to the IDH-defined subtype. In one cited SNUC study: TP53 41.7% (5/12), CDKN2A/2B loss 33.3% (4/12), MYC amplification 33.3% (4/12), SETD2 mutation 25% (3/12). Another cohort reported TP53 55%, KIT-activating mutations 45%, PI3K-pathway mutations 36% among IDH-mutant carcinomas. Primary molecular study 2018 and review 2023 (thawani2023thecontemporarymanagement pages 14-15, mito2018immunohistochemicaldetectionand pages 1-2)
Differential diagnosis SWI/SNF-deficient sinonasal carcinomas are distinct from genuine SNUC and generally lack the characteristic IDH2 mutation. SMARCB1 deficiency reported in 9/142 cases (6%) in one review summary; <150 SMARCB1-deficient sinonasal carcinoma cases reported overall in pathology overview; all studied SWI/SNF-deficient cases lacked oncogenic IDH2 mutations. Pathology overview/review, 2022-2023 (thawani2023thecontemporarymanagement pages 14-15, agaimy2022proceedingsofthe pages 1-2)
Imaging/staging Imaging usually shows a large invasive noncalcified mass; staging may use AJCC or modified Kadish. MRI pattern described qualitatively; no robust SNUC-specific pooled sensitivity/specificity identified here. Review, 2023 (thawani2023thecontemporarymanagement pages 14-15)
Multimodality local control Combined-modality therapy is favored; trimodality improves locoregional control over less intensive approaches. Locoregional control: trimodality 63.9% vs bimodality 49.2% vs surgery alone 31.3%. Meta-analytic summary in review, 2023 (thawani2023thecontemporarymanagement pages 14-15)
Radiotherapy note IMRT at adequate dose is preferred; some benefit statements derive from broader sinonasal-cancer data rather than SNUC-only cohorts. RT dose threshold commonly cited as >=60 Gy; where survival/toxicity comparisons are mentioned, they are not always SNUC-exclusive. Mixed evidence; review, 2021-2023; explicitly not always SNUC-specific (thawani2023thecontemporarymanagement pages 14-15)
Induction chemotherapy-guided management Response to induction chemotherapy is a major prognostic and treatment-selection factor in SNUC. Amit cohort: 95 treatment-naive patients; regimen cisplatin 60-80 mg/m2 day 1 plus etoposide 100-120 mg/m2 or docetaxel 75 mg/m2 days 1-3 every 21 days for 1-5 cycles (median 3). Review summary reports 5-year survival 66% with IC+CRT and 43% with IC+surgery+RT; progression-free survival 74% vs 55%, respectively. Primary cohort summarized in 2023 review; outcome table in 2022 critical review (thawani2023thecontemporarymanagement pages 14-15, konig2020theroleof pages 5-6)
Survival Prognosis remains poor overall despite aggressive therapy. Median survival ~22 months reported in pathology study background; historical review table reports 5-year OS ranging from 19% (XRT only) to 66% in modern IC-guided multimodality cohorts. Primary pathology background 2018 and review-of-studies 2022 (mito2018immunohistochemicaldetectionand pages 1-2, konig2020theroleof pages 5-6)
Current trial: pembrolizumab Ongoing phase II study tests adding pembrolizumab to neoadjuvant chemotherapy in locally advanced SNUC. NCT05925491; recruiting; phase II; planned n=28; pembrolizumab 200 mg + cisplatin 75 mg/m2 (or carboplatin AUC5) + docetaxel 75 mg/m2 every 3 weeks for 3 cycles; primary endpoint ORR. Interventional trial registry, first posted 2023; active update 2026 (NCT05925491 chunk 1)
Current trial: enasidenib Ongoing phase II study targets IDH2-mutant recurrent/metastatic or unresectable sinonasal/skull-base tumors including SNUC. NCT06176989; recruiting; phase II; planned n=40; enasidenib 100 mg orally daily; includes documented somatic IDH2 R140/R172 mutations; SNUC-specific secondary endpoints include CBR, PFS, OS. Interventional trial registry, first posted 2023; active update 2026 (NCT06176989 chunk 1)
All-sinonasal context (explicitly not SNUC-specific) Overall sinonasal malignancies are rare as a group; this should not be mistaken for SNUC incidence. Sinonasal malignancies overall: 0.5-1.0/100,000 incidence. All-sinonasal review statistic, not SNUC-specific, 2023 (thawani2023thecontemporarymanagement pages 14-15)

Table: This table compiles the most supported, SNUC-specific findings available from the gathered sources, emphasizing quantitative epidemiology, presentation, molecular features, treatment outcomes, and active trials. It also explicitly flags when a statistic applies to all sinonasal malignancies rather than genuine SNUC.

1. Disease information

Definition and classification

SNUC is a rare, highly aggressive carcinoma of the nasal cavity or paranasal sinuses showing epithelial differentiation but no definable squamous, glandular, melanocytic, lymphoid, or neuroendocrine lineage. It was first described in 1986 in eight patients and was initially thought to arise from Schneiderian epithelium or nasal ectoderm. Contemporary classification has narrowed the diagnosis by removing molecularly defined mimics from the former “wastebasket” category. (turrizanoni2022molecularbiomarkersin pages 5-6, thawani2023thecontemporarymanagement pages 12-14, thawani2023thecontemporarymanagement pages 14-15)

A useful exact description from the 2018 molecular-pathology study is that SNUC “is considered a diagnosis of exclusion, and has historically represented a heterogeneous group of tumors.” That study showed why combined morphology, immunohistochemistry, and sequencing are now necessary. (mito2018immunohistochemicaldetectionand pages 1-2)

Identifiers and synonyms

  • Preferred name: sinonasal undifferentiated carcinoma.
  • Synonyms: SNUC; undifferentiated carcinoma of the sinonasal tract; undifferentiated carcinoma of the nasal cavity and paranasal sinuses.
  • MONDO/OMIM/Orphanet: A confidently verified disease-specific identifier was not available in the retrieved evidence; these fields should remain unresolved rather than assigning an identifier for a broader sinonasal cancer.
  • ICD-10-CM: No histology-specific SNUC code. Coding is anatomical, usually C30.0 (malignant neoplasm of nasal cavity) or a C31.x paranasal-sinus code.
  • ICD-O: Registration requires a topography code for the involved sinonasal site plus the applicable undifferentiated-carcinoma morphology code; local registry verification is advised.
  • MeSH: No clearly verified SNUC-specific descriptor was identified; indexing generally uses broader “Paranasal Sinus Neoplasms,” “Nasal Cavity Neoplasms,” and “Carcinoma, Undifferentiated.”

These are aggregated disease-resource mappings, whereas the clinical and molecular evidence below derives from cohorts, case series, pathology collections, and trial registries.

2. Etiology, risk, and protective factors

Causal and susceptibility factors

The initiating cause is unknown. SNUC is ordinarily a sporadic somatic cancer, not a Mendelian syndrome. Recurrent IDH2 mutations define a large molecular subgroup but are tumor drivers/biomarkers rather than inherited susceptibility variants. No validated germline causal gene, founder mutation, carrier frequency, penetrance estimate, or familial inheritance pattern has been established. (thawani2023thecontemporarymanagement pages 14-15, mito2018immunohistochemicaldetectionand pages 1-2)

Possible environmental associations are weak and largely hypothesis-generating. Seven of eight patients in the original series had tobacco exposure; individual occupational histories included coal work and chrome plating with exposure to sulfuric/chromic acids, nickel, zinc, copper, and metallic dust. Nickel refining and softwood/furniture exposure have also been reported. These observations are too sparse and confounded to establish causality. (thawani2023thecontemporarymanagement pages 12-14)

EBV is not established as causal. One geographically stratified study detected EBV RNA in 7/11 Asian cases but 0/11 Western cases; a later Taiwanese series found no EBV in 36 cases, and additional studies failed to confirm an association. HPV DNA likewise is generally absent; p16 staining should not be interpreted as proof of HPV-driven disease. (thawani2023thecontemporarymanagement pages 12-14, thawani2023thecontemporarymanagement pages 14-15)

Protective factors and gene–environment interaction

No genetic protective allele, diet, medication, vaccine, or lifestyle intervention has been shown specifically to prevent SNUC. No reproducible gene–environment interaction has been demonstrated. Avoidance of tobacco and recognized occupational carcinogens is prudent general cancer prevention, but its SNUC-specific effect size is unknown.

3. Phenotypes

SNUC usually has adult, insidious onset followed by rapid progression. Symptoms often mimic benign rhinosinusitis, delaying diagnosis. In a systematic review of 140 patients, nasal obstruction occurred in 20.0%, epistaxis in 17.1%, diplopia or other visual symptoms in 15.0%, and headache in 12.1%; orbital involvement was present in 42.9%. In another 128-patient analysis, 72.9% had stage IV disease at diagnosis. (thawani2023thecontemporarymanagement pages 12-14)

Suggested phenotype annotations include:

  • Nasal obstruction — HP:0001742, Nasal obstruction; progressive, sometimes unilateral.
  • Epistaxis — HP:0000421.
  • Headache — HP:0002315.
  • Diplopia — HP:0000651.
  • Visual impairment — HP:0000505; may result from orbital/apical or optic-pathway invasion.
  • Proptosis — HP:0000520, when orbital extension displaces the globe.
  • Facial pain — HP:0010828; cranial neuropathy or facial numbness may accompany perineural/skull-base spread.
  • Anosmia — HP:0000458, biologically plausible with superior nasal/olfactory involvement, although a reliable SNUC-specific frequency was not retrieved.
  • Cervical lymphadenopathy — HP:0025280, reflecting regional metastasis.

Severity is commonly high and progression continuous rather than episodic. Quality of life can be impaired by nasal obstruction, bleeding, pain, disturbed vision, cranial-nerve dysfunction, disfigurement, and treatment effects on smell, vision, swallowing, speech, dentition, endocrine function, and cognition. No validated SNUC-specific EQ-5D, SF-36, or PROMIS distribution was identified; quantitative quality-of-life claims should therefore not be extrapolated from mixed sinonasal cohorts.

4. Genetic, molecular, and epigenetic information

IDH-defined genuine SNUC

The best-established alteration is a somatic IDH2 hotspot mutation at codon R172, with reported frequencies of 10/16 (62.5%), 6/11 (54.5%), and 14/17 (82.4%) across molecular series. In a 193-tumor multi-institutional study, mutation-specific IDH1/2 immunohistochemistry was positive in 26/53 SNUCs (49%) and 0/132 histologic mimics. Sequencing found frequent IDH2 R172 substitutions—R172S/G associated with strong staining and R172T with weak or sometimes negative staining—and a rare IDH1 p.R132C mutation. Consequently, negative mutation-specific IHC does not exclude an IDH mutation; sequencing is required when suspicion remains. (thawani2023thecontemporarymanagement pages 14-15, mito2018immunohistochemicaldetectionand pages 1-2)

Reported co-alterations include TP53, CDKN2A/CDKN2B loss, MYC amplification, SETD2, activating KIT, and PI3K-pathway mutations. In one 12-case IDH2-mutant set, TP53 alterations occurred in 41.7%, CDKN2A/2B loss and MYC amplification each in 33.3%, and SETD2 mutation in 25%. A separate analysis reported TP53 in 55%, activating KIT alterations in 45%, and PI3K-pathway alterations in 36% of IDH-mutant carcinomas. These are somatic tumor findings and are not established ACMG-classified germline variants. (thawani2023thecontemporarymanagement pages 14-15, mito2018immunohistochemicaldetectionand pages 1-2)

Mechanistically, neomorphic mutant IDH2 is expected to convert α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate, inhibiting α-ketoglutarate-dependent dioxygenases and producing widespread epigenetic/differentiation abnormalities. This mechanistic model is biologically well established across IDH-mutant cancers, but SNUC-specific methylome, metabolomic, and causal functional data remain limited.

Suggested annotations: IDH2 (HGNC:5383); IDH1 (HGNC:5382); GO:0045944 positive regulation of transcription, GO:0016491 oxidoreductase activity, GO:0007049 cell cycle, GO:0006281 DNA repair, GO:0043067 regulation of programmed cell death, and GO:0048870 cell motility.

Critical distinction from SWI/SNF-deficient tumors

Historical reports sometimes counted loss of SMARCB1/INI1 or SMARCA4/BRG1 as SNUC alterations. Current expert pathology instead recognizes SMARCB1-deficient sinonasal carcinoma, SMARCB1-deficient adenocarcinoma, SMARCA4-deficient carcinoma, and SMARCA4-deficient teratocarcinosarcoma as distinct SWI/SNF-driven entities. The pathology overview states that studied SWI/SNF-deficient tumors lacked the oncogenic IDH2 mutations “characteristic of genuine SNUC.” (agaimy2022proceedingsofthe pages 1-2)

Thus, loss of nuclear INI1 or BRG1 should prompt reclassification rather than annotation as a SNUC “causal gene.” SMARCB1 maps to 22q11.2 and SMARCA4 to chromosome 19; their proteins are chromatin-remodeling tumor suppressors. In SWI/SNF-deficient tumors, biallelic deletion or inactivating mutation causes protein loss and altered transcriptional/differentiation programs. (thawani2023thecontemporarymanagement pages 14-15, agaimy2022proceedingsofthe pages 1-2)

No validated SNUC modifier genes, germline pathogenic variants, recurrent constitutional chromosomal abnormality, or population allele-frequency estimates were identified. WES/WGS, single-cell, spatial-transcriptomic, proteomic, lipidomic, and metabolomic findings remain research-grade rather than validated disease characteristics.

5. Environmental and infectious information

Potential non-genetic contributors are tobacco and occupational exposure to nickel, chromium/chromic acid, metallic dust, coal-related material, and wood/furniture dust, but evidence is based on very small historical series. Alcohol, diet, exercise, radiation, ambient air pollution, and specific medications have no established SNUC-specific associations. EBV and HPV are not accepted etiologic agents for genuine SNUC. (thawani2023thecontemporarymanagement pages 12-14, thawani2023thecontemporarymanagement pages 14-15)

6. Mechanism and pathophysiology

A defensible causal model is:

  1. Upstream event: an acquired epithelial-cell driver, commonly IDH2 R172 mutation, arises in sinonasal mucosa.
  2. Molecular consequence: mutant enzyme generates D-2-hydroxyglutarate, plausibly disrupting dioxygenase-dependent chromatin regulation and differentiation.
  3. Cellular consequence: lineage maturation fails while proliferation, cell-cycle activity, DNA-repair programs, invasion, and survival pathways become dysregulated. Gene-expression comparison with sinonasal squamous carcinoma identified differences involving CLCA2, ARID2, MAP1LC3A, SMAD4, HELLS, MAPKAPK5-AS1, and KRT16, although direction and functional importance require further validation. (thawani2023thecontemporarymanagement pages 14-15)
  4. Tissue consequence: sheets/nests of high-grade epithelial cells develop necrosis, marked mitotic activity, lymphovascular invasion, perineural invasion, and destructive growth through bone.
  5. Clinical consequence: obstruction and bleeding arise locally; orbital/skull-base invasion produces visual and neurologic symptoms; lymphovascular dissemination produces cervical-node and distant metastases. (thawani2023thecontemporarymanagement pages 12-14, thawani2023thecontemporarymanagement pages 14-15)

Relevant cell ontology suggestions are CL:0000066 epithelial cell, CL:0000115 endothelial cell for vascular invasion, CL:0000235 macrophage, and CL:0000084 T cell for the tumor microenvironment. The precise tumor cell of origin is unresolved. Suggested biological-process terms include GO:0008283 cell population proliferation, GO:0007155 cell adhesion, GO:0030335 positive regulation of cell migration, GO:0001525 angiogenesis, GO:0006915 apoptotic process, and GO:0006355 regulation of DNA-templated transcription.

No reproducible SNUC-specific immune-cell atlas, immune-evasion mechanism, metabolic signature beyond the inferred IDH oncometabolite pathway, or CRISPR dependency screen was found.

7. Anatomical structures affected

The primary sites are the nasal cavity (UBERON:0001707) and paranasal sinuses (UBERON:0001825), particularly ethmoid, maxillary, sphenoid, and frontal sinuses. Contiguous spread may involve sinonasal mucosa, bone, orbit, cribriform plate, anterior or middle cranial fossa, dura, brain, cranial nerves, nasopharynx, clivus, palate, pterygoid structures, and facial soft tissue. AJCC T4b disease includes orbital apex, middle cranial fossa, dura, brain, non-V2 cranial nerves, nasopharynx, or clivus. (thawani2023thecontemporarymanagement pages 62-70, thawani2023thecontemporarymanagement pages 14-15)

At tissue level this is an epithelial malignancy with destructive invasion into connective tissue, bone, vessels, nerves, and sometimes neural tissue. Regional dissemination involves cervical lymph nodes; distant sites include lung, bone, brain, and liver. Disease is usually centered asymmetrically or unilaterally but can cross midline when extensive. Nuclear and cytosolic compartments are mechanistically relevant to transcription/chromatin regulation and IDH2 metabolism, respectively.

8. Temporal development

Presentation is generally in middle-aged or older adults, with median age approximately 50–60 years. Onset is often clinically insidious because early symptoms resemble inflammatory sinonasal disease, but biological progression is rapid. Most tumors are locally advanced at diagnosis, and the course without effective treatment is progressive rather than relapsing-remitting. (thawani2023thecontemporarymanagement pages 12-14)

Staging should use AJCC eighth-edition site-specific TNM. Modified Kadish staging is also reported: stage A is confined to the nasal cavity, while stage D denotes nodal or distant metastasis. Treatment-induced remission can occur, especially after platinum-based induction therapy, but local, regional, and distant relapse remain important. No credible spontaneous-remission pattern is established. The early induction-chemotherapy response interval is a critical decision window because response strongly informs the choice of definitive local therapy. (thawani2023thecontemporarymanagement pages 14-15)

9. Inheritance, epidemiology, and population

SNUC accounts for approximately 3–5% of sinonasal carcinomas/malignancies. SEER recorded 318 cases from 1973–2010, corresponding to an annual incidence of approximately 0.02 per 100,000. Incidence was estimated at 0.03 per 100,000 in males and 0.01 in females, implying roughly a 3:1 incidence ratio. The median age is 50–60 years. (thawani2023thecontemporarymanagement pages 12-14, mito2018immunohistochemicaldetectionand pages 1-2)

For context, all sinonasal malignancies together occur at approximately 0.5–1.0 per 100,000; that broader statistic must not be assigned to SNUC itself. (thawani2023thecontemporarymanagement pages 14-15)

No reliable ethnic predisposition, endemic distribution, founder effect, consanguinity association, anticipation, mosaicism, carrier state, or reproductive recurrence risk is established. Because the relevant variants are usually somatic, Mendelian inheritance fields are not applicable.

10. Diagnostics

Clinical and imaging work-up

Evaluation should include nasal endoscopy, contrast-enhanced CT for bone destruction, and contrast-enhanced MRI for orbit, skull base, dura, brain, and perineural disease. Typical imaging shows a large, noncalcified invasive mass; MRI is approximately isointense to muscle on T1, iso- to hyperintense on T2, and heterogeneously enhancing after gadolinium. Chest/body imaging or FDG-PET/CT is appropriate for nodal and distant staging. Imaging is not histologically specific. (thawani2023thecontemporarymanagement pages 14-15)

Biopsy and pathology

Histology shows small-to-medium pleomorphic cells in ribbons, sheets, nests, trabeculae, or organoid arrangements, with scant cytoplasm, hyperchromatic nuclei, prominent nucleoli, high mitotic activity, necrosis, and possible lymphovascular/perineural invasion. Broad-spectrum epithelial markers support carcinoma: AE1/AE3, CAM5.2, CK7, CK8, and CK19 are commonly positive or variably expressed. (thawani2023thecontemporarymanagement pages 14-15, thawani2023thecontemporarymanagement pages 12-14)

A practical exclusion panel should include:

  • p40/CK5/6: usually negative in genuine SNUC; diffuse positivity favors squamous carcinoma.
  • S100/SOX10 and melanocytic markers Melan-A/HMB45: exclude melanoma and selected neural/multiphenotypic tumors.
  • CD45: excludes lymphoma.
  • Desmin/myogenin: exclude rhabdomyosarcoma.
  • Synaptophysin/chromogranin/INSM1: evaluate neuroendocrine carcinoma; focal neuroendocrine-marker expression can occur in SNUC without neuroendocrine morphology.
  • NUT IHC: excludes NUT carcinoma.
  • INI1/SMARCB1 and BRG1/SMARCA4: retained expression supports genuine SNUC; loss defines separate SWI/SNF-deficient entities.
  • EBER-ISH: excludes EBV-associated nasopharyngeal-type carcinoma/NK-T-cell processes where appropriate.
  • Mutation-specific IDH1/2 IHC followed by tumor NGS: identifies the IDH-mutant subgroup, but sequencing is essential after negative/weak IHC because R172T and rare IDH1 variants may be missed. (thawani2023thecontemporarymanagement pages 14-15, mito2018immunohistochemicaldetectionand pages 1-2, agaimy2022proceedingsofthe pages 1-2)

Genetic and omics testing

The clinically relevant test is somatic tumor profiling, preferably an NGS panel covering IDH2 R172/R140, IDH1 R132, TP53, CDKN2A/B, MYC copy number, PI3K-pathway genes, and other actionable alterations. RNA sequencing may be used if a fusion-defined differential remains possible. WES/WGS can help difficult cases but has no established advantage over focused DNA/RNA profiling in routine SNUC. Germline testing, CMA, karyotyping, mitochondrial testing, and repeat-expansion testing are not routine unless personal/family history independently suggests a hereditary syndrome.

Differential diagnosis and screening

Major alternatives are olfactory neuroblastoma, high-grade neuroendocrine carcinoma, poorly differentiated squamous carcinoma, NUT carcinoma, SMARCB1- or SMARCA4-deficient carcinoma, lymphoma, melanoma, rhabdomyosarcoma, Ewing sarcoma, and EBV-associated carcinoma. Precise separation is mandatory because prognosis and targeted trials differ. (mito2018immunohistochemicaldetectionand pages 1-2, agaimy2022proceedingsofthe pages 1-2)

There is no population screening test, blood biomarker, liquid-biopsy standard, carrier screen, or surveillance program for asymptomatic individuals.

11. Outcome and prognosis

SNUC has historically had poor outcomes, with an often-cited median survival of approximately 22 months despite multimodal therapy. Regional metastasis occurs in approximately 5–16% and distant metastasis in 20–30%. (thawani2023thecontemporarymanagement pages 12-14, mito2018immunohistochemicaldetectionand pages 1-2)

Outcomes vary substantially with stage, resectability, radiotherapy dose, treatment combination, and induction response. A review table reported historical five-year overall survival of 19% with radiotherapy alone versus 46% with surgery plus radiotherapy in one series, and 60% versus 9%, respectively, in another. In the modern induction-guided cohort, summarized five-year survival was 66% for induction chemotherapy followed by chemoradiation and 43% for induction followed by surgery and radiotherapy; corresponding progression-free estimates were 74% and 55%. These nonrandomized comparisons are subject to response-based selection and should not be interpreted as universal regimen effects. (konig2020theroleof pages 5-6)

Across a meta-analysis, locoregional control was 63.9% with trimodality therapy, 49.2% with bimodality therapy, and 31.3% with surgery alone; another meta-analysis did not find a survival advantage for three modalities over two, though combination treatment remained superior to a single modality. (thawani2023thecontemporarymanagement pages 14-15)

Adverse prognostic features include T4/skull-base or intracranial extension, nodal/distant disease, inability to deliver definitive local treatment, and poor induction-chemotherapy response. IDH-mutant tumors may have a more favorable biology in some series, but mutation-specific prognostication is not yet sufficiently standardized for treatment de-escalation.

Long-term morbidity may include visual loss, cranial neuropathy, anosmia, dysphagia, xerostomia, dental injury, endocrine dysfunction, cognitive effects, and facial/skull-base surgical morbidity. Robust SNUC-specific disability and patient-reported-outcome statistics are unavailable.

12. Treatment and current applications

Standard multidisciplinary strategy

There is no randomized, universally accepted curative algorithm. Care should occur at a high-volume skull-base/head-and-neck center with expert pathology review.

  1. Induction chemotherapy: A major contemporary approach uses a platinum doublet to measure chemosensitivity. In a 95-patient treatment-naïve cohort, cisplatin 60–80 mg/m² on day 1 was combined with etoposide 100–120 mg/m² or docetaxel 75 mg/m² on days 1–3 every 21 days for 1–5 cycles (median three). Favorable responders generally had superior outcomes and were often directed to definitive chemoradiation; poor responders with resectable disease were considered for surgery followed by adjuvant therapy. (thawani2023thecontemporarymanagement pages 14-15)
  2. Radiotherapy: Definitive or postoperative IMRT, usually at least 60 Gy in the reviewed literature, is a central component. IMRT improves dose conformity near the optic apparatus and brain and was associated in retrospective data with better survival/recurrence outcomes and lower toxicity than older conventional techniques. Proton therapy may reduce normal-tissue dose in selected skull-base cases, but SNUC-specific comparative evidence is limited. (thawani2023thecontemporarymanagement pages 14-15)
  3. Surgery: Endoscopic endonasal or craniofacial resection is used when complete resection is anatomically feasible and consistent with functional goals. Open craniofacial resection has increasingly been replaced by endoscopic or combined approaches in selected patients. Surgery alone is inadequate for most advanced SNUCs. (thawani2023thecontemporarymanagement pages 14-15)
  4. Systemic agents: Cisplatin, etoposide, docetaxel, paclitaxel, and 5-fluorouracil are used in multimodal regimens. Recurrent/metastatic management is individualized because no SNUC-specific systemic standard has prospective phase III validation.

Suggested NCI Thesaurus intervention concepts include platinum-based chemotherapy, cisplatin, carboplatin, etoposide, docetaxel, paclitaxel, fluorouracil, intensity-modulated radiation therapy, proton-beam radiation therapy, endoscopic resection, craniofacial resection, pembrolizumab, and enasidenib. Exact NCIt codes should be resolved against the current NCIt release rather than inferred.

Recent and emerging research

NeoPeSino—NCT05925491 is a recruiting, single-arm phase II study in 28 planned patients with treatment-naïve stage III–IVB SNUC. It administers pembrolizumab 200 mg, cisplatin 75 mg/m² or carboplatin AUC5, and docetaxel 75 mg/m² every three weeks for three cycles before standard local therapy; the primary endpoint is RECIST 1.1 objective response. The hypothesis is that adding perioperative checkpoint blockade may maintain activity while reducing overall treatment burden, but no efficacy results are yet available. First posted June 29, 2023; ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05925491. (NCT05925491 chunk 1)

NCT06176989 is an NCI single-arm phase II trial enrolling 40 patients with recurrent/metastatic or unresectable IDH2 R140/R172-mutant sinonasal/skull-base tumors, including SNUC. Enasidenib 100 mg orally daily is given continuously; endpoints include PFS, safety, and SNUC-specific clinical benefit, PFS, and OS. This is the clearest real-world translation of the IDH2 discovery, but it remains experimental. First posted December 20, 2023; ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06176989. (NCT06176989 chunk 1)

No approved SNUC-specific gene therapy, cell therapy, RNA therapy, CAR-T product, or pharmacogenomic dosing guideline exists. The enasidenib trial also explores UGT1A1 genotype–toxicity association, but this is not yet a validated SNUC pharmacogenomic recommendation. (NCT06176989 chunk 1)

Supportive care should include pain management, nutrition, dental care before radiation, ophthalmology and endocrinology when relevant, swallowing/speech therapy, psychosocial support, smoking cessation, and rehabilitation for visual, neurologic, or functional deficits.

13. Prevention

Primary prevention: No SNUC-specific intervention is proven. Avoid tobacco and minimize occupational exposure to nickel, chromium compounds, metallic and wood dust using engineering controls and personal protective equipment. This is precautionary rather than supported by a quantified SNUC risk reduction. No vaccine is applicable because HPV and EBV are not established causes.

Secondary prevention: Population screening is not recommended because incidence is approximately 0.02/100,000/year and no validated precursor lesion or screening assay exists. Persistent unilateral obstruction, recurrent epistaxis, cranial neuropathy, proptosis, or visual change warrants prompt endoscopic examination and imaging.

Tertiary prevention: Complete multimodal therapy, dental/visual/endocrine protection, rehabilitation, and surveillance imaging aim to reduce recurrence and treatment complications. Genetic counseling and family screening are not routinely indicated because SNUC is not established as inherited.

14. Other species and natural disease

No well-established naturally occurring veterinary counterpart specifically equivalent to molecularly confirmed human SNUC was identified. Dogs, cats, and other animals develop nasal carcinomas, but those should not be annotated as SNUC without matching histology and molecular classification. There is no evidence of zoonotic transmission or cross-species contagion. Comparative orthology of IDH2, TP53, and SWI/SNF genes is strong, but evolutionary conservation alone does not establish a natural-disease model.

15. Model organisms and experimental systems

The retrieved literature did not identify a standardized genetically engineered mouse, rat, zebrafish, organoid, patient-derived xenograft, or authenticated cell-line model that reproducibly recapitulates genuine IDH2-mutant SNUC. Most mechanistic inference comes from human tumor tissue, retrospective cohorts, immunohistochemistry, and targeted sequencing. The 2018 primary study analyzed 53 expert-confirmed SNUCs and 132 mimics, demonstrating diagnostic specificity of mutant-IDH IHC but not providing a causal animal model. (mito2018immunohistochemicaldetectionand pages 1-2)

Priority model-development needs are:

  • patient-derived organoids and xenografts retaining IDH2 R172 and native epigenetic state;
  • conditional IDH2 R172 knock-in in sinonasal epithelial progenitors;
  • isogenic cell systems to test whether mutant IDH2 is sufficient for blocked differentiation;
  • immunocompetent models for checkpoint therapy;
  • functional screens for IDH, PI3K, DNA-repair, and chromatin dependencies.

Such models would permit testing enasidenib, chemotherapy resistance, radiation response, and rational immunotherapy combinations. Their key limitation will be uncertainty about the human cell of origin and the rarity/heterogeneity of source tissue.

Evidence appraisal and key gaps

The strongest evidence consists of expert-reviewed human pathology cohorts, registry epidemiology, and retrospective multidisciplinary series. There are no randomized SNUC-specific trials, and most treatment comparisons are vulnerable to stage, resectability, institutional, and response-selection bias. Recent molecular classification also means that older cohorts may be contaminated by entities now excluded from SNUC. The most consequential knowledge gaps are validated incidence by modern molecular definition, prospective treatment outcomes, SNUC-specific patient-reported quality of life, immune and single-cell atlases, liquid-biopsy biomarkers, preventive risk estimates, and faithful experimental models.

Principal sources and publication dates

  • Thawani R, et al. The contemporary management of cancers of the sinonasal tract in adults. CA Cancer J Clin. 2023;73:72–112. Published online/issue information reported August 2023. DOI/URL: https://doi.org/10.3322/caac.21752. (thawani2023thecontemporarymanagement pages 14-15, thawani2023thecontemporarymanagement pages 12-14)
  • Mito JK, et al. Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas. Am J Surg Pathol. 2018;42:1067–1075. Published August 2018. DOI/URL: https://doi.org/10.1097/PAS.0000000000001064. Exact abstract conclusion: “IDH-mutant sinonasal carcinoma may represent a distinct pathobiological entity with therapeutic implications.” (mito2018immunohistochemicaldetectionand pages 1-2)
  • Agaimy A. SWI/SNF-deficient Sinonasal Neoplasms: An Overview. Head Neck Pathol. 2022;16:168–178. Published March 21, 2022. DOI/URL: https://doi.org/10.1007/s12105-022-01416-x. (agaimy2022proceedingsofthe pages 1-2)
  • Turri-Zanoni M, et al. Molecular Biomarkers in Sinonasal Cancers: New Frontiers in Diagnosis and Treatment. Curr Oncol Rep. 2022;24:55–67. Published January 2022. DOI/URL: https://doi.org/10.1007/s11912-021-01154-3. (turrizanoni2022molecularbiomarkersin pages 5-6)

PMIDs were not exposed in the retrieved full-text records and therefore are not fabricated here; DOI links provide stable primary-source resolution.

References

  1. (thawani2023thecontemporarymanagement pages 12-14): Rajat Thawani, Myung Sun Kim, Asad Arastu, Zizhen Feng, Malinda T. West, Nicholas F. Taflin, Kyaw Zin Thein, Ryan Li, Mathew Geltzeiler, Nancy Lee, Clifton David Fuller, Jennifer R. Grandis, Charalampos S. Floudas, Michael C. Heinrich, Ehab Hanna, and Ravi A. Chandra. The contemporary management of cancers of the sinonasal tract in adults. CA: A Cancer Journal for Clinicians, 73:72-112, Aug 2023. URL: https://doi.org/10.3322/caac.21752, doi:10.3322/caac.21752. This article has 174 citations and is from a domain leading peer-reviewed journal.

  2. (NCT05925491 chunk 1): Pembrolizumab in Locally Advanced Sinonasal Carcinoma. Istituti Clinici Scientifici Maugeri SpA. 2024. ClinicalTrials.gov Identifier: NCT05925491

  3. (thawani2023thecontemporarymanagement pages 14-15): Rajat Thawani, Myung Sun Kim, Asad Arastu, Zizhen Feng, Malinda T. West, Nicholas F. Taflin, Kyaw Zin Thein, Ryan Li, Mathew Geltzeiler, Nancy Lee, Clifton David Fuller, Jennifer R. Grandis, Charalampos S. Floudas, Michael C. Heinrich, Ehab Hanna, and Ravi A. Chandra. The contemporary management of cancers of the sinonasal tract in adults. CA: A Cancer Journal for Clinicians, 73:72-112, Aug 2023. URL: https://doi.org/10.3322/caac.21752, doi:10.3322/caac.21752. This article has 174 citations and is from a domain leading peer-reviewed journal.

  4. (NCT06176989 chunk 1): Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors. National Cancer Institute (NCI). 2024. ClinicalTrials.gov Identifier: NCT06176989

  5. (mito2018immunohistochemicaldetectionand pages 1-2): Jeffrey K. Mito, Justin A. Bishop, Peter M. Sadow, Edward B. Stelow, William C. Faquin, Stacey E. Mills, Jeffrey F. Krane, Christopher A. French, Christopher D.M. Fletcher, Jason L. Hornick, Lynette M. Sholl, and Vickie Y. Jo. Immunohistochemical detection and molecular characterization of idh-mutant sinonasal undifferentiated carcinomas. The American Journal of Surgical Pathology, 42:1067–1075, Aug 2018. URL: https://doi.org/10.1097/pas.0000000000001064, doi:10.1097/pas.0000000000001064. This article has 70 citations.

  6. (agaimy2022proceedingsofthe pages 1-2): Abbas Agaimy. Proceedings of the north american society of head and neck pathology, los angeles, ca, march 20, 2022: swi/snf-deficient sinonasal neoplasms: an overview. Head and Neck Pathology, 16:168-178, Mar 2022. URL: https://doi.org/10.1007/s12105-022-01416-x, doi:10.1007/s12105-022-01416-x. This article has 31 citations and is from a peer-reviewed journal.

  7. (konig2020theroleof pages 5-6): Marton König, Terje Osnes, Øyvind Bruland, Kirsten Sundby Hall, Åse Bratland, and Torstein R. Meling. The role of adjuvant treatment in craniofacial malignancy: a critical review. Frontiers in Oncology, Aug 2022. URL: https://doi.org/10.3389/fonc.2020.01402, doi:10.3389/fonc.2020.01402. This article has 10 citations.

  8. (turrizanoni2022molecularbiomarkersin pages 5-6): Mario Turri-Zanoni, Giacomo Gravante, and Paolo Castelnuovo. Molecular biomarkers in sinonasal cancers: new frontiers in diagnosis and treatment. Current Oncology Reports, 24:55-67, Jan 2022. URL: https://doi.org/10.1007/s11912-021-01154-3, doi:10.1007/s11912-021-01154-3. This article has 40 citations and is from a peer-reviewed journal.

  9. (thawani2023thecontemporarymanagement pages 62-70): Rajat Thawani, Myung Sun Kim, Asad Arastu, Zizhen Feng, Malinda T. West, Nicholas F. Taflin, Kyaw Zin Thein, Ryan Li, Mathew Geltzeiler, Nancy Lee, Clifton David Fuller, Jennifer R. Grandis, Charalampos S. Floudas, Michael C. Heinrich, Ehab Hanna, and Ravi A. Chandra. The contemporary management of cancers of the sinonasal tract in adults. CA: A Cancer Journal for Clinicians, 73:72-112, Aug 2023. URL: https://doi.org/10.3322/caac.21752, doi:10.3322/caac.21752. This article has 174 citations and is from a domain leading peer-reviewed journal.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 6
Resolved 6
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 6
On topic 4
Off topic 0

All extracted references resolved successfully.